1. Home
  2. JYNT vs STTK Comparison

JYNT vs STTK Comparison

Compare JYNT & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo The Joint Corp.

JYNT

The Joint Corp.

HOLD

Current Price

$8.92

Market Cap

149.5M

Sector

Miscellaneous

ML Signal

HOLD

Logo Shattuck Labs Inc.

STTK

Shattuck Labs Inc.

HOLD

Current Price

$3.97

Market Cap

119.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JYNT
STTK
Founded
2010
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Multi-Sector Companies
Biotechnology: Pharmaceutical Preparations
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
149.5M
119.0M
IPO Year
2014
2020

Fundamental Metrics

Financial Performance
Metric
JYNT
STTK
Price
$8.92
$3.97
Analyst Decision
Strong Buy
Buy
Analyst Count
2
5
Target Price
$17.00
$4.00
AVG Volume (30 Days)
83.5K
469.9K
Earning Date
11-06-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$54,176,002.00
$1,000,000.00
Revenue This Year
$6.11
N/A
Revenue Next Year
$6.13
N/A
P/E Ratio
N/A
N/A
Revenue Growth
10.47
N/A
52 Week Low
$7.50
$0.69
52 Week High
$13.47
$4.00

Technical Indicators

Market Signals
Indicator
JYNT
STTK
Relative Strength Index (RSI) 56.82 83.32
Support Level $8.64 $3.15
Resistance Level $9.07 $3.29
Average True Range (ATR) 0.24 0.23
MACD -0.01 0.05
Stochastic Oscillator 67.31 91.26

Price Performance

Historical Comparison
JYNT
STTK

About JYNT The Joint Corp.

The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The Company has one operating business segment; The Franchise Operations segment which is comprised of the operating activities of the franchise business unit. The Franchise Operations segment derives revenue from customers by providing access to the Company's franchise license, which represents symbolic intellectual property.

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

Share on Social Networks: